Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-101 in Wet Age-Related Macular Degeneration
NCT07811726Phase 2Recruiting
- Sponsor
- NexThera Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in exudative macular degeneration comparing NT-101 High Dose (0.2 mM) with Placebo (2 arms). Primary endpoint: Best Corrected Visual Acuity at 12 weeks. Started Jun 2026; status: recruiting.
02
Drugs
NT-101
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT07811726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07811726.